## Jing Zhou

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7619163/publications.pdf

Version: 2024-02-01

		304743	395702
35	2,381	22	33
papers	citations	h-index	g-index
37	37	37	3398
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Intracellular calcium response of primary cilia of tubular cells to modulated shear stress under oxidative stress. Biomicrofluidics, 2020, 14, 044102.	2.4	5
2	Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease. Kidney International, 2020, 98, 1225-1241.	5.2	37
3	Ciliotherapy: Remote Control of Primary Cilia Movement and Function by Magnetic Nanoparticles. ACS Nano, 2019, 13, 3555-3572.	14.6	22
4	Personalized Nanotherapy by Specifically Targeting Cell Organelles To Improve Vascular Hypertension. Nano Letters, 2019, 19, 904-914.	9.1	20
5	Retromer associates with the cytoplasmic amino-terminus of polycystin-2. Journal of Cell Science, 2018, 131, .	2.0	8
6	Guided tissue organization and disease modeling in a kidney tubule array. Biomaterials, 2018, 183, 295-305.	11.4	11
7	Predictors of Nonuse of a Highâ€Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladibâ€Thrombolysis in Myocardial Infarction 52 (SOLIDâ€TIMI 52) Trial. Journal of the American Heart Association, 2017, 6, .	3.7	8
8	A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Reports, 2017, 18, 3167-3177.	6.4	32
9	Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease. Molecular and Cellular Biology, 2017, 37, .	2.3	98
10	Distinct oxylipin alterations in diverse models of cystic kidney diseases. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 1562-1574.	2.4	29
11	Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT― Circulation, 2016, 133, e463.	1.6	O
12	<i>Gα12</i> is required for renal cystogenesis induced by <i>Pkd1</i> inactivation. Journal of Cell Science, 2016, 129, 3675-3684.	2.0	17
13	Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Scientific Reports, 2016, 6, 32087.	3.3	58
14	Disruption of polycystin-L causes hippocampal and thalamocortical hyperexcitability. Human Molecular Genetics, 2016, 25, 448-458.	2.9	24
15	Regulation of polycystin-1 ciliary trafficking by motifs at its C-terminus and polycystin-2 but not cleavage at GPS site. Journal of Cell Science, 2015, 128, 4063-73.	2.0	34
16	Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nature Communications, 2015, 6, 8715.	12.8	571
17	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. Circulation, 2015, 132, 1224-1233.	1.6	267
18	Integrative Mouse and Human Studies Implicate <i>ANGPT1</i> and <i>ZBTB7C</i> as Susceptibility Genes to Ischemic Injury. Stroke, 2015, 46, 3514-3522.	2.0	17

#	Article	IF	Citations
19	Effects of Shiga Toxin Type 2 on a Bioengineered Three-Dimensional Model of Human Renal Tissue. Infection and Immunity, 2015, 83, 28-38.	2.2	23
20	Aberrant Glycosylation and Localization of Polycystin-1 Cause Polycystic Kidney in an AQP11 Knockout Model. Journal of the American Society of Nephrology: JASN, 2014, 25, 2789-2799.	6.1	37
21	Bardet–Biedl syndrome proteins 1 and 3 regulate the ciliary trafficking of polycystic kidney disease 1 protein. Human Molecular Genetics, 2014, 23, 5441-5451.	2.9	65
22	TGF-β–Activated Kinase 1 Is Crucial in Podocyte Differentiation and Glomerular Capillary Formation. Journal of the American Society of Nephrology: JASN, 2014, 25, 1966-1978.	6.1	17
23	Feasibility and Reproducibility of Three-Dimensional Echocardiographic Assessment of Right Ventricular Size and Function in Pediatric Patients. Journal of the American Society of Echocardiography, 2014, 27, 903-910.	2.8	26
24	AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achievement of National Cholesterol Education Program–Adult Treatment Panel III Low-Density Lipoprotein Cholesterol Goals Among High-Risk Patients. Journal of the American College of Cardiology, 2014, 63, 430-433.	2.8	50
25	L-type calcium channel modulates cystic kidney phenotype. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1518-1526.	3.8	31
26	Asleep at the Switch: MEK Kinases Control Transit to Gliogenesis in Developing Cortex. Neuron, 2012, 75, 940-942.	8.1	1
27	Aberrant Regulation of Planar Cell Polarity in Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2010, 21, 1521-1532.	6.1	92
28	Cystâ€lining epithelial cells from ADPKD kidneys have a mechanoâ€ciliary dysfunction. FASEB Journal, 2006, 20, A339.	0.5	0
29	Immortalized epithelial cells from human autosomal dominant polycystic kidney cysts. American Journal of Physiology - Renal Physiology, 2003, 285, F397-F412.	2.7	76
30	Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes. Nature Genetics, 1999, 21, 160-161.	21.4	149
31	Identification, distribution, and tissular origin of the $\hat{l}\pm 5$ (IV) and $\hat{l}\pm 6$ (IV) collagen chains in the developing human intestine. Developmental Dynamics, 1998, 212, 437-447.	1.8	40
32	Identification, distribution, and tissular origin of the $\hat{l}\pm 5$ (IV) and $\hat{l}\pm 6$ (IV) collagen chains in the developing human intestine. Developmental Dynamics, 1998, 212, 437-447.	1.8	1
33	Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nature Genetics, 1997, 17, 179-181.	21.4	420
34	Detection of 12 novel mutations in the collagenous domain of the COL4A5 gene in Alport syndrome patients. Human Mutation, 1995, 5, 197-204.	2.5	34
35	Deletion spanning the 5′ ends of both the COL4A5 and COL4A6 genes in a patient with Alport's syndrome and leiomyomatosis. Human Mutation, 1994, 4, 195-198.	2.5	24